Table 2 Univariate and multivariate analyses of progression-free survival and overall survival
OS | PFS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||||||
Characteristics | Median | p-value | HR | 95% CI | p-value | Median | p-value | HR | 95% CI | p-value |
Age, years | ||||||||||
< 70 | 15.2 | 0.645 | 7.4 | 0.236 | ||||||
≥ 70 | 10.3 | 6.4 | ||||||||
Sex | ||||||||||
Male | 12.6 | 0.223 | 7.7 | 0.171 | ||||||
Female | 14.9 | 3.9 | ||||||||
ECOG PS | ||||||||||
0 or 1 | 16.5 | < 0.0001 | 0.001 | 7.7 | 0.007 | 0.028 | ||||
2 | 4.1 | 5.28 | 2.06–13.54 | 2.7 | 2.67 | 1.11–6.41 | ||||
Disease status | ||||||||||
Primary metastatic | 14.9 | 0.762 | 7.4 | 0.825 | ||||||
Recurrent | 9.9 | 6.4 | ||||||||
Histology | ||||||||||
Well or moderate | 12.6 | 7.8 | ||||||||
Poor | 12.8 | 0.733 | 5.9 | 0.815 | ||||||
Signet ring cell | 5.9 | 3.9 | ||||||||
Combined, others | 4.5 | 3.4 | ||||||||
HER2 status | ||||||||||
IHC 3+ | 12.6 | 0.658 | 6.9 | 0.938 | ||||||
IHC 2+ with SISH + | 17.0 | 6.8 | ||||||||
Liver metastasis | ||||||||||
No | 15.2 | 0.312 | 8.3 | 0.066 | 0.137 | |||||
Yes | 10.0 | 6.4 | 1.66 | 0.85–3.23 | ||||||
Peritoneal metastasis | ||||||||||
No | 14.9 | 0.413 | 6.9 | 0.621 | ||||||
Yes | 10.0 | 5.0 | ||||||||
Amount of ascites | ||||||||||
No/small/moderate | 15.2 | 0.001 | 0.005 | 7.4 | 0.016 | 0.073 | ||||
Massive | 5.9 | 4.54 | 1.57–13.09 | 3.9 | 2.47 | 0.92–6.65 | ||||
Surgical resection | ||||||||||
No | 9.9 | 0.004 | 0.025 | 5.9 | 0.002 | 0.022 | ||||
Surgery | 30.8 | 0.25 | 0.08–0.84 | 20.3 | 0.29 | 0.10–0.84 | ||||
Chemotherapy | ||||||||||
Capecitabine/Cisplatin | 12.6 | 0.649 | 6.5 | 0.795 | ||||||
5-FU/Cisplatin | 12.8 | 8.3 | ||||||||